Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 2:18 AM
Ignite Modification Date: 2025-12-26 @ 12:49 AM
NCT ID: NCT02121834
Description: None
Frequency Threshold: 5
Time Frame: None
Study: NCT02121834
Study Brief: A Study of LY3050258 in Healthy Participants
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Cohort A-D Placebo Placebo daily for 28 days None None 0 12 5 12 View
Cohort A: 10 mg LY3050258 10 mg LY3050258, daily for 28 days None None 0 11 4 11 View
Cohort B: 30 mg LY3050258 30 mg LY3050258, daily for 28 days None None 0 9 2 9 View
Cohort C: 90 mg LY3050258 90 mg LY3050258, daily for 28 days None None 0 10 3 10 View
Cohort D: 180 mg LY3050258 180 mg LY3050258, daily for 28 days None None 0 9 6 9 View
Cohort E: 360 mg LY3050258 360 mg LY3050258, daily for 28 days None None 0 9 4 9 View
Cohort E: Placebo Placebo daily for 28 days None None 0 3 2 3 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Abdominal pain upper SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 16.1 View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 16.1 View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 16.1 View
Toothache SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 16.1 View
Vomiting SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 16.1 View
Application site erythema SYSTEMATIC_ASSESSMENT General disorders MedDRA 16.1 View
Application site irritation SYSTEMATIC_ASSESSMENT General disorders MedDRA 16.1 View
Application site pain SYSTEMATIC_ASSESSMENT General disorders MedDRA 16.1 View
Application site rash SYSTEMATIC_ASSESSMENT General disorders MedDRA 16.1 View
Application site reaction SYSTEMATIC_ASSESSMENT General disorders MedDRA 16.1 View
Application site warmth SYSTEMATIC_ASSESSMENT General disorders MedDRA 16.1 View
Vessel puncture site reaction SYSTEMATIC_ASSESSMENT General disorders MedDRA 16.1 View
Upper respiratory tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 16.1 View
Viral upper respiratory tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 16.1 View
Arthropod bite SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA 16.1 View
Laceration SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA 16.1 View
Electrocardiogram t wave abnormal SYSTEMATIC_ASSESSMENT Investigations MedDRA 16.1 View
Back pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA 16.1 View
Myalgia SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA 16.1 View
Dysgeusia SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 16.1 View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 16.1 View
Hypoaesthesia SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 16.1 View
Urine odour abnormal SYSTEMATIC_ASSESSMENT Renal and urinary disorders MedDRA 16.1 View
Nail discolouration SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA 16.1 View
Rash maculo-papular SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA 16.1 View
Haematoma SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA 16.1 View